Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

An Open-Label, Phase III Study of Platinum-Gemcitabine With or Without Nivolumab in the First-Line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT04458909
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:27:13.420647+00:00
Published At
2024-09-19T00:00:00+00:00
Record Updated At
2025-10-03
Results Posted At
2024-09-19
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Metastatic Nasopharyngeal Carcinoma", "Metastatic Nasopharyngeal Keratinizing Squamous Cell Carcinoma", "Metastatic Nasopharyngeal Nonkeratinizing Carcinoma", "Metastatic Nasopharyngeal Undifferentiated Carcinoma", "Nasopharyngeal Nonkeratinizing Carcinoma", "Recurrent Nasopharyngeal Carcinoma", "Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma", "Recurrent Nasopharyngeal Undifferentiated Carcinoma", "Stage IV Nasopharyngeal Carcinoma AJCC v8", "Stage IVA Nasopharyngeal Carcinoma AJCC v8", "Stage IVB Nasopharyngeal Carcinoma AJCC v8"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2025-10-03"
protocolSection.identificationModule.nctId
"NCT04458909"
protocolSection.identificationModule.officialTitle
"An Open-Label, Phase III Study of Platinum-Gemcitabine With or Without Nivolumab in the First-Line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma"
protocolSection.statusModule.overallStatus
"TERMINATED"
protocolSection.designModule.phases
["PHASE3"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2024-09-19"

Study condition terms

  • Metastatic Nasopharyngeal Carcinoma (protocolSection.conditionsModule.conditions)
  • Metastatic Nasopharyngeal Keratinizing Squamous Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Metastatic Nasopharyngeal Nonkeratinizing Carcinoma (protocolSection.conditionsModule.conditions)
  • Metastatic Nasopharyngeal Undifferentiated Carcinoma (protocolSection.conditionsModule.conditions)
  • Nasopharyngeal Nonkeratinizing Carcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Nasopharyngeal Carcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Nasopharyngeal Undifferentiated Carcinoma (protocolSection.conditionsModule.conditions)
  • Stage IV Nasopharyngeal Carcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
  • Stage IVA Nasopharyngeal Carcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
  • Stage IVB Nasopharyngeal Carcinoma AJCC v8 (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.